Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
EpiThany, Inc.
Washington, District of Columbia, United Statesepithany.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
EpiThany has advanced its lead therapeutic vaccine candidate into Phase II clinical trials targeting solid tumors such as breast cancer. The company’s technology enables robust Th1-driven anti-tumor immunity across a spectrum of cancers. No published pivotal or late-stage results were identified; ongoing studies focus on safety and efficacy in early-to-mid clinical development.
- Therapeutic areas
- Oncology
- Modalities
- Therapeutic vaccinesDNA vaccinesmRNA vaccinesRecombinant polypeptides
- Industry
- Biotech
02
Partnerships
Collaborations with University of Washington/Tumor Vaccine Groupindustry partners mentioned generally
Beyond the preview
Go deeper on EpiThany, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EpiThany, Inc..